Loading...
Identification of pretreatment indicators of response to specific antidepressants is highly desirable, but clinically useful tools are not available. To explore possible predictors, two research groups analyzed data from the 17-site, industry-supported iSPOT-D trial, in which 1006 adults with major depression were randomized to 8-week, open treatment with escitalopram, sertraline, or extended-release venlafaxine and were assessed by blinded raters.
Arnow and colleagues analyzed response by clinical subtype (atypical, 153; melancholic, 107; anxious, 130; various combinations of two subtypes, 256; all three subtypes, 107; no subtype, 253). No specific medication differences in improvement or remission were seen by subtype; 37% of patients with…